Stockreport

ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF Anktiva received Breakthrough Therapy Designation and approval from the FDA based on its safety and efficacy outcomes, which appear to have "best-in-class" potential. [Read more]